

## Special Issue

# Pharmacomicrobiomics in Non-communicable Disease

### Message from the Guest Editor

Pharmacomicrobiomics is a new branch that deals with investigating the interactions between the microbiome and the response to xenobiotics, defined as the effect of changes in the microbiome on drug action and toxicity. Noncommunicable diseases (NCDs) are the result of a combination of genetic, physiological, environmental and behavioral factors.

Recent data have shown that one in four drugs that we routinely take to treat nonintestinal diseases alter the gut microbiome, causing adverse events, with an increase in bacterial resistance. This complexity means that pharmacological studies require a molecular biology approach studying cell signaling and the complex host-microbe-drug interactions.

Consequently, investigating the concept of pharmacomicrobiotics is important for understanding how the microbiota is involved in drug responses. Hence, the purpose of this Special Issue is to provide an overview of the relationship between pharmacomicrobiomics and NCDs in order to better understand the molecular mechanisms and how this new branch could lead to a new therapeutic approach.

---

### Guest Editor

Dr. Amedeo Amedei

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

---

### Deadline for manuscript submissions

closed (31 January 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/7991](https://mdpi.com/si/7991)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).